Dihydrouracil Dehydrogenase (NADP)
"Dihydrouracil Dehydrogenase (NADP)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxidoreductase involved in pyrimidine base degradation. It catalyzes the catabolism of THYMINE; URACIL and the chemotherapeutic drug, 5-FLUOROURACIL.
| Descriptor ID |
D042943
|
| MeSH Number(s) |
D08.811.682.660.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dihydrouracil Dehydrogenase (NADP)".
Below are MeSH descriptors whose meaning is more specific than "Dihydrouracil Dehydrogenase (NADP)".
This graph shows the total number of publications written about "Dihydrouracil Dehydrogenase (NADP)" by people in this website by year, and whether "Dihydrouracil Dehydrogenase (NADP)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihydrouracil Dehydrogenase (NADP)" by people in Profiles.
-
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26(3):133-7.
-
Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014 Dec; 106(12).
-
Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008 Jan 01; 14(1):8-13.
-
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002 Mar 15; 20(6):1683-91.